- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00897481
Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy
A Retrospective Case-Control Study of Melanoma Patients Who Have Undergone Sentinel Lymph Node Biopsy
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help the study of cancer in the future.
PURPOSE: This laboratory study is looking at tumor tissue samples from patients with melanoma who have undergone sentinel lymph node biopsy.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
OBJECTIVES:
- Develop a predictive model for sentinel lymph node biopsy positivity in patients with melanoma who have undergone sentinel lymph node biopsy.
- Develop a survival model for relapse based on sentinel lymph node biopsy positivity.
- Assess the genetic determinants in primary melanomas that predict a metastatic phenotype and thereby improve understanding of the biology of the metastases in melanoma.
OUTLINE: This is a retrospective, case-controlled, multicenter study. Patients are stratified according to Breslow thickness of the tumor (0.75-1.50 mm vs 1.51- 4 mm vs > 4 mm) and gender.
Archived tumor tissue is analyzed by immunohistochemistry (IHC) for AP2, vascular endothelial growth factor, MMP 2, MCM4, and others, if feasible. Sentinel node biopsies are analyzed by IHC for CD31, LYVE-1, and D2-40 expression. RNA and DNA are also extracted for genetic expression studies and mutation analysis (e.g., BRAF, NRAS, PTEN, CDKN2A).
Patient data related to relapse and recurrence is collected, if available.
Peer reviewed and funded or endorsed by Cancer Research UK
PROJECTED ACCRUAL: A total of 1,000 patients will be accrued for this study.
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Lieux d'étude
-
-
England
-
Leeds, England, Royaume-Uni, LS9 7TF
- Recrutement
- Leeds Cancer Centre at St. James's University Hospital
-
Contact:
- Julia Newton Bishop, MD
- Numéro de téléphone: 44-113-206-4668
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
Confirmed diagnosis of cutaneous melanoma
- Breslow thickness > 0.75 mm
- Has undergone sentinel lymph node biopsy
- No primary melanoma that has not originated in the skin
- No multiple primary melanomas
- Currently under clinical followup OR discharged from follow up within the past 3 months
PATIENT CHARACTERISTICS:
- No other malignancy except for nonmelanoma skin cancer or cervical carcinoma in situ
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Plan d'étude
Comment l'étude est-elle conçue ?
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
|---|
|
Predictive model for sentinel lymph node biopsy positivity
|
|
Survival model for relapse
|
|
Genetic determinants in primary melanomas that predict a metastatic phenotype
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chaise d'étude: Julia Newton Bishop, MD, Leeds Cancer Centre at St. James's University Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CRUK-LCC-06/Q1206/149
- CDR0000532943 (Identificateur de registre: PDQ (Physician Data Query))
- EU-20706
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .